Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Fennec Pharmaceuticals, Inc. (NASDAQ: FENC).

Full DD Report for FENC

You must become a subscriber to view this report.


Recent News from (NASDAQ: FENC)

Fennec Pharmaceuticals: NDA Submission Will Be A Major Catalyst
Fennec Pharmaceuticals ( FENC ) has a single product in a (very) late stage. A TPT member asked us about Fennec Pharma in July, so we ran it through the IOMachine. The IOMachine, if you recall, performs a four-factor test on a stock and arrives at an investibility opinion. While running FNEC t...
Source: SeekingAlpha
Date: September, 05 2018 14:31
September 13 Meeting Will Explore Chemo-Induced Hearing Loss in Pediatrics
WASHINGTON, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Young adult survivors of childhood cancer and parents of children with cancer are invited to participate via webcast in a workshop on Chemotherapy-Induced Hearing Loss in Pediatrics, taking place in the DC metro area on September 13, 2018. This...
Source: GlobeNewswire
Date: September, 05 2018 07:00
Fennec Provides Business Update and Announces Second Quarter 2018 Financial Results
Publication of PEDMARK TM SIOPEL 6 Clinical Data in The New England Journal of Medicine Joined Russell 3000 Index Strong financial position with $25.6 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (...
Source: GlobeNewswire
Date: August, 13 2018 06:00
Fennec Pharmaceuticals Receives Positive Opinion on the Pediatric Investigation Plan From European Medicines Agency for PEDMARK(TM) and Confirmation of Eligibility for a Pediatric Use Marketing Authorization
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has accepted the Company’s pediatric inv...
Source: GlobeNewswire
Date: August, 07 2018 06:00
Fennec Pharma: Assured Patience To Be Greatly Rewarded
Shares of Fennec Pharma (FENC) continue to slide on no news and dwindling cash, enticing shorts to visit. Despite the short-term pain for bulls, they should be confident in PEDMARK's inherent worth and ability to profit investors going forward. The following article will shed light on what is ...
Source: SeekingAlpha
Date: July, 17 2018 04:25
Fennec Announces Publication of Pedmark(TM) Siopel 6 Clinical Data in the New England Journal of Medicine
SIOPEL 6 met primary endpoint (p=0.002) 48% reduction in the incidence of hearing loss No evidence of tumor protection RESEARCH TRIANGLE PARK, N.C., June 21, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company...
Source: GlobeNewswire
Date: June, 21 2018 06:00
Fennec Pharmaceuticals Set to Join Russell 3000 Index
RESEARCH TRIANGLE PARK, N.C., June 11, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxi...
Source: GlobeNewswire
Date: June, 11 2018 06:00
Clover's Weekly Leaflet
We look back at the week that was and look forward to the week to come. Viking Therapeutics takes advantage of good times and raises once more Viking Therapeutics ( VKTX ) announced Thursday that they intend to raise an additional $65M at $9/share to advance their clinical pipeline...
Source: SeekingAlpha
Date: June, 11 2018 01:51
3 Reasons Why Fennec Pharma Will Be Bought Out For A >50% Premium Over Today's Prices
Let me premise the following article by stating that a buyout is not the only hope for Fennec Pharma ( FENC ). I would never introduce an idea with a buyout as the only hope. In actuality, this is now a clinically derisked company with a needed drug on their hands and the FDA behind their ba...
Source: SeekingAlpha
Date: June, 06 2018 07:01
Fennec Provides Business Update and Announces First Quarter 2018 Financial Results
PEDMARK TM granted Breakthrough Therapy and Fast Track Designations by FDA Actively preparing for NDA submission later this year Strong financial position with $26.7 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., May 14, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceutical...
Source: GlobeNewswire
Date: May, 14 2018 06:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-088.898.798.98918.70166,617
2018-05-1711.2211.0611.6010.9189,651

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-072,8798,15435.3078Short
2018-12-062,14412,96416.5381Cover
2018-12-042,5649,26027.6890Cover
2018-12-036,60621,74530.3794Cover
2018-11-301,7614,88136.0787Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FENC.


About Fennec Pharmaceuticals, Inc. (NASDAQ: FENC)

Logo for Fennec Pharmaceuticals, Inc. (NASDAQ: FENC)

Fennec Pharmaceuticals Inc. is a clinical stage biotechnology company developing Sodium Thiosulfate STS , a chemo protectant against hearing loss associated with platinum based chemotherapy.

 

Contact Information

 

 

Current Management

  • Rostislav Raykov / CEO
  • Robert Andrade / CFO
  • Mark Gowland / Controller
  • Khalid Islam / Chairman, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Marco Brughera / Compensation Committee Member, Nominating Committee Member
    • Marco Brughera has been a director since October . He is the Global Head of the SigmaTau Rare Disease Business Unit., a position he has held since October . Currently he is also President of SigmaTau Pharmaceuticals Inc., President of SigmaTau Research Switzerland S.A. and Chief Executive Officer of SigmaTau Pharma Ltd. From January through October , Dr. Brughera held several other positions with the SigmaTau Group, including Corporate Research and Development Managing Director of SigmaTau Industrie Farmaceutiche Riunite S.p.A. From December through January , Dr. Brughera served on the Board of Directors of Gentium S.p.A., a publicly traded biopharmaceutical company. From to , Dr. Brughera served as the Vice President of Preclinical Development at Nerviano Medical Sciences S.r.l. NMS Group , a pharmaceutical oncologyfocused integrated discovery and development company. He also served as the Managing Director at Accelera S.r.l., an independent contract research organization affiliated with the NMS Group. From to , Dr. Brughera held several senior level positions in the areas of discovery and development with Pharmacia Corporation and Pfizer, Inc. Prior to , he held various positions at Pharmacia amp Upjohn Company, Inc. and Farmitalia Carlo Erba S.p.A., an Italian pharmaceutical company. Dr. Brughera earned his degree in veterinary medicine from the University of Milan and is a European Registered Toxicologist.
  • Adrian Haigh / Audit Committee Member, Nominating Committee Member
  • Chris A. Rallis / Audit Committee Member, Compensation Committee Member
  • Rostislav Raykov /

Current Share Structure

  • Market Cap: $208,651,178 - 05/16/2018
  • Issue and Outstanding: 18,464,706 - 03/16/2018

 


Recent Filings from (NASDAQ: FENC)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: May, 10 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 20 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 19 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: April, 13 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: March, 29 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 23 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: FENC)

Daily Technical Chart for (NASDAQ: FENC)


Stay tuned for daily updates and more on (NASDAQ: FENC)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: FENC)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FENC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of FENC and does not buy, sell, or trade any shares of FENC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/